Market News Video
MNV MNV 10 Oversold Stocks You Need To Know About
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Interesting June 2016 Stock Options for PFE
Monday, October 26, 11:58 AM ET, by Market News Video Staff

Consistently, one of the more popular stocks people enter into their stock options watchlist at ...

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick
Tuesday, October 27, 11:48 AM ET, by Market News Video Staff

A study of analyst recommendations at the major brokerages shows that Pfizer Inc (PFE) is ...

See Which Of The Latest 13F Filers Holds Abbott Laboratories
Tuesday, October 27, 1:20 PM ET, by Market News Video Staff

At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F ...

Noteworthy ETF Inflows: IVV, PFE, BAC, PEP
Thursday, October 29, 11:04 AM ET, by Market News Video Staff

Symbols mentioned in this story: IVV, PFE, BAC, PEP Exchange traded funds (ETFs) trade just ...

Notable Thursday Option Activity: CME, PFE, GOOGL
Thursday, October 29, 1:47 PM ET, by Market News Video Staff

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume ...

  More articles:  1 2 3 4 5 6 7 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Abbott   Administration   Elquis   Food   Molecular   Myers   NYSE   Pfizer   Xalkori   advanced   approved   atrial   benefit   business   cancer   capsules   clinical   compared   diagnostic   disease   drug   each   embolism   evaluate   further   least   lung   lymphoma   marketing   mortality   offers   over   partnered   patients   pharmacies   positive   risk   said   small   some   stroke   subset   systemic   targeting   that   treatment   which   with   worldwide   years
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Portfolio Channel Stock Market Definitions

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2015, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.